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Purpose. The present study evaluated the effect of Hypericum perforatum dry extract in an experimental model of binge eating (BE).
Methods. BE for highly palatable food (HPF) was evoked in female rats by three 8-day cycles of food restriction/re-feeding and acute
stress on the test day (day 25). Stress was induced by preventing access to HPF for 15min, while rats were able to see and smell
it. Hypericum perforatum dry extract was given by gavage. Results. Only rats exposed to both food restrictions and stress exhibited
BE. The doses of 250 and 500mg/kg of Hypericum perforatum extract significantly reduced the BE episode, while 125mg/kg
was ineffective. The same doses did not affect HPF intake in the absence of BE. The dose of 250mg/kg did not significantly
modify stress-induced increase in serum corticosterone levels, suggesting that the effect on BE is not due to suppression of the
stress response The combined administration of 125mg/kg of Hypericum perforatum together with Salidroside, active principle
of Rhodiola rosea, produced a synergic effect on BE. Conclusions. The present results indicate for the first time that Hypericum
perforatum extracts may have therapeutic properties in bingeing-related eating disorders.
1. Introduction
Episodes of binge eating (BE) in humans are characterized by
compulsive, nonhomeostatic consumption of an unusually
large quantity of highly palatable food (HPF) in a short
period of time. Even though not hungry, subjects eat more
rapidly than normal until feeling uncomfortably full. These
episodes are accompanied by subjective sense of loss of
control over eating and are associated with feeling of distress,
disgust, depression, being guilty about overeating, and eating
alone because of embarrassment [1].
BE represents a central feature of bulimia nervosa, in
which episodes of BE are followed by behaviours aimed at
avoiding weight gain, such as self-induced vomiting. Intense
and persistent BE episodes represent a typical phenomenon
occurring also in subjects suffering from binge eating
disorder (BED) [2] that is probably the most prevalent
eating disorder [3]. It is characterized by repeated episodes
of BE in the absence of compensatory behaviours to avoid
weight gain. The DMS-IV-TR [1] indicates among diagnostic
criteria for BED that BE episodes should occur at least 2
days per week for six months. The BED is associated with
significant medical and psychiatric comorbidity [4–6]. It is
estimated that BE afflicts approximately 5% of the US adult
population at some time in their life [7], and it contributes
to aggravate obesity and associated pathologies [3, 8–10].
A large body of evidence suggests that dieting, stress
and negative affective states represent possible triggers of
BE in patients suffering from BED or bulimia nervosa
[11, 12]. Indeed, dieting periods are a common finding
in the history of binge eaters, although hunger per se
appears to be not enough to induce BE in the absence of
stress and negative affective states [13, 14]. Considerable
evidence suggests that BE may be caused by a unique
interaction between dieting and stress; thus, environmental
stress and a history of cyclic food restrictions may be
responsible for its precipitation and maintenance [15–17].
Accordingly, recurring food restrictions are consistently
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the strongest predictor of overeating in response to stress
[11].
Despite a growing recognition of the consequences of
bulimia nervosa and of BED on public health, satisfactory
treatments are not available at present [18]. Medications that
have been suggested to reduce BE in clinical studies, like
topiramate [19, 20] or sibutramine [21, 22] are associated
with a variety of adverse side effects, which represent a
serious problem during chronic treatment [23–25]; in par-
ticular, sibutramine has been recently withdrawn from the
European market. Fluoxetine has been approved by the FDA
for bulimia nervosa, but evidence for its efficacy is reported
inconclusive [26]. Apparently, treatment of BED and bulimia
nervosa cannot simply rely on pharmacological agents aimed
at reducing food intake in general, like serotonergic drugs.
Innovative treatments for bulimia nervosa and BED, devoid
of severe side effects, are strongly needed.
BE episodes appear to be characterized by uncontrollable
urge to obtain and consume food, which is similar to that
exhibited by addicted individuals towards drug of abuse.
Evidence is accumulating that excessive intake of certain
foods under specified conditions produces behaviours and
changes in the brain that resemble an addiction-like state
[27–31]. Neural systems that motivate and reinforce drug
abuse have been proposed to underlie also behaviours
associated with compulsive food seeking and food intake
[32–36]. In this regard, it is interesting to note that several
drugs that influence alcohol addiction have been reported to
reduce BE in experimental models (such as naloxone [37],
naltrexone, and baclofen [38, 39] and topiramate [40]) as
well as in clinical studies [41–43].
Previous studies have shown that acute administration
of Hypericum perforatum extract attenuates alcohol intake in
genetically selected alcohol-preferring rats by influencing the
motivational properties of ethanol [44–50].
Extracts of Hypericum perforatum, the common plant
usually called St. John’s wort, are known to exert antide-
pressant effects in humans [51–55] and antidepressant-
like actions in laboratory animals in different experimental
models [56–61].
Hypericum perforatum contains a variety of biologically
active compounds, including the naphthodianthrones hyper-
icin and pseudohypericin, and the phloroglucinol derivatives
hyperforin, adhyperforin, and several flavonoids [51, 62, 63].
A further reason of interest in the effect of Hypericum
perforatum on BE is raised by the finding that it has been
reported to exhibit antistress properties. In this regard,
several papers have shown that some of its active principles
bind to CRF-1 receptors and exhibit antagonist activity at
these receptors [64–67]. Moreover, Hypericum perforatum
extracts have been shown to reduce the hypothalamic-
pituitary-adrenal (HPA) axis activation following chronic
treatment [68], to reduce restraint stress-induced increases
in plasma ACTH and corticosterone levels following acute
administration [69], and to counteract the negative effects
of corticosterone on hippocampal cell proliferation [70].
Since stress is a key determinant of BE, a reduction of the
response to stress might represent an effective mechanism
for suppression of BE. Therefore, we thought it of interest
to evaluate whether Hypericum perforatum extracts attenuate
BE evoked in female rats by combining stress and food
restrictions [40].
Moreover, the effect of Hypericum perforatum on BE was
also evaluated in combination with salidroside, active princi-
ple of the dry extract of Rhodiola rosea (family Crassulaceae)
[71, 72].
Rhodiola rosea roots contain a variety of biologically
active compounds, including organic acids, flavonoids, tan-
nins, and phenolic compounds. Phenylpropane and phe-
nylethane phenolic glycosides, such as salidroside, rosavin,
syringing, and triandrin are considered the most important
active principles [71].
Recently our group reported that Rhodiola rosea extract
and salidroside suppress BE, interfering with stress mecha-
nisms [73].
In the present study, it was evaluated whether the
combined administration of Hypericum perforatum and
salidroside might offer advantages over their separate admin-
istration.
2. Material and Methods
A preclinical model has been recently developed by our
group to investigate the neuro- and psychobiology of BE and
to identify innovative pharmacological treatments [40]. This
model is derived with modifications from the original model
developed by Hagan et al. [74]. It uses female rats in relation
to the higher prevalence of binge-type eating disorders in
women than inmen [1, 3] and combines three 8-day cycles of
food restriction/refeeding and acute stress (on the 25th day)
to evoke BE for HPF in Sprague-Dawley rats.
2.1. Animals. Female Sprague-Dawley rats (Charles River,
Calco, Como, Italy) were used. Their body weight was
225–250 g at the beginning of the experiments. Rats were
acclimated to individual cages under a 12 h light/dark cycle
(lights on at 08:00 a.m.) with ad libitum chow and water
for 2 weeks prior to the experiments. They were kept in a
room at constant temperature (20–22◦C) and humidity (45–
55%). Rats were kept in individual cages with metallic walls;
the floor and the front wall were made of metallic grid. The
dimensions of the cage floor were 30 cm × 30 cm; the cage
was 30 cm high. A front door (30 cm × 20 cm) made of
metallic grid was present in the anterior wall of the cage to
get access to the inside of the cage; the remaining part of the
front wall was equipped with a drinking burette.
2.2. Diet. Animals were offered standard rat food pellets
(4RF18, Mucedola, Settimo Milanese, Italy (2.6 kcal/g). The
HPF was a paste in texture, prepared by mixing Nutella
(Ferrero, Alba, Torino, Italy) chocolate cream (5.33 kcal/g;
56%, 31%, and 7% from carbohydrate, fat, and protein,
resp.), grounded food pellets (4RF18, Mucedola, Settimo
Milanese, Italy), and water in the following weight/weight
percent ratio: 52% Nutella, 33% food pellets, and 15% water.
The HPF diet had a caloric content of 3.63 kcal/g. HPF was
offered in a coffee cup; the handle of the cup was inserted into
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the metallic grid of the anterior wall of the cage and fixed to
the wall. Standard pellets were offered inside a metallic grid
container that was hung on the anterior wall of the cage; it
was removed from the cage to measure its weight in order to
determine food pellet intake.
2.3. The Stressful Procedure. For 15min, the coffee cup
containing HPF was placed inside a metallic grid container
that was hanged up on the anterior wall of the cage. In these
conditions, the animal was able to see the cup in which it
received HPF on day 5, 6, 13, and 14 of the first two cycles,
was able to see the HPF itself, and to smell its odour. In
this 15min period, the rat engaged in repeated movements
of the forepaws, head, and trunk aimed at obtaining the
HPF, but it was not able to reach it. This procedure was
adopted to generate a mild stressful condition that causes
a significant increase in serum corticosterone levels [41].
Rats underwent the stressful procedure between 10.00 and
12.00 h. After 15min, the cup was placed inside the cage of
rats of the stress groups, so that HPF became accessible to
them.
2.4. Drug Treatment. Hypericum perforatum dry extract,
containing 0.1% hypericin and 3.8% hyperforin, was a
generous gift of Indena, Milano, Italy. It was dissolved in
2% ethanol and water and administered by gavage (2ml/kg)
at doses of 125–500mg/kg [75] 1 h before access to HPF.
Salidroside, an active principle of Rhodiola rosea extract,
was purchased from Chengdu Biopurify Phytochemicals
Ltd. (Chengdu, Sichuan, China). It was dissolved in 2%
ethanol and water and administered by gavage (2ml/kg)
1 h before access to HPF at the dose of 312 µg/kg. Control
rats received vehicle administration by gavage (2ml/kg). In
experiment 4, the volume of administration was 1ml/kg for
both compounds.
2.5. Experimental Procedure
Experiment 1. Effect of Repeated Food Restrictions and Acute
Stress of HPF Intake in Female Rats. Forty female rats were
used. They were divided in 4 groups of 10 animals, matched
for body weight and daily food intake: (1) the nonrestricted
and not exposed to stress group (NR +NS), (2) the restricted
and not exposed to stress group (R + NS), (3) the non-
restricted and exposed to stress group (NR + S), and (4) the
restricted and exposed to stress group (R + S).
Rats were subjected to 3 consecutive 8-day cycles fol-
lowed by the final test on day 25. Each 8-day cycle was
as follows: (a) the control group (NR + NS) had chow ad
libitum for 4 days, on days 5-6, it received chow ad libitum
+ HPF for 2 h (from 10:00 a.m., i.e., 2 h after the beginning
of the light phase of the cycle); on days 7-8, it had chow
ad libitum; on day 25, it was not exposed to stress; (b) the
second group (R + NS) had chow restricted to 66% of the
usual intake for 4 days, was offered chow ad libitum and HPF
for 2 h on days 5-6 and only chow on days 7-8; on day 25, it
was not exposed to stress; (c) the third group had chow and
HPF as controls (NR + NS), but on the test day (day 25), it
was exposed to stress (NR + S); (d) the fourth group (R + S)
had food available like group R + NS and on day 25, it was
exposed to stress.
The 8-day cycle was repeated three times, but in the third
cycle, the animals did not have access to HPF on day 21 and
22.
It has been recently reported by our group that in the
estrous phase of the ovarian cycle, female rats do not exhibit
BE in the adopted model [76], while in all the other three
phase of the ovarian cycle they exhibit BE without significant
differences in intensity. Therefore, immediately after the test
on day 25, vaginal smears were collected and analysed under
microscope to assess the ovarian phase, and data from rats
in the estrous phase were not included in the statistical
analysis. Vaginal smears were analysed by an experienced
experimenter blind to treatment conditions.
Food intake was expressed as mean kcal/kg ingested ±
S.E.M.; it was measured for 2 h, since previous experiments
showed no differences among groups after this period. HPF
intake was measured at 15, 30, 60, and 120min after access to
it. Food pellet intake was measured only at 2 h, in relation to
the findings of previous studies showing that the food pellet
intake was very small and to avoid disturbance to the animals
during the test.
Experiment 2. Effect of Hypericum perforatum Extract on BE
Evoked by Cycles of Food Restriction and Exposure to Acute
Stress. Eighty female rats were used. They were divided in
2 groups of 40 animals, matched for body weight and daily
food intake: (1) the nonrestricted and not exposed to stress
group (NR + NS) and (2) the restricted and exposed to
stress group (R + S). Only these two groups were used since
Experiment 1 confirmed that BE is not expressed in the R +
NS and NR + S groups. Rats were subjected to 3 consecutive
8-day cycles followed by the final test on day 25, as reported
in Experiment 1.
Each group of 40 rats was divided in 4 subgroups of 10
rats, treated, respectively, with vehicle or with Hypericum
perforatum dry extract (125, 250, or 500mg/kg) given by
gavage 1 h before access to HPF. Food intake was expressed
as mean kcal/kg ingested ± S.E.M. HPF intake was measured
at 15, 30, 60, and 120min after access to it. Food pellet intake
was measured only at 2 h.
Experiment 3. Effect of Hypericum perforatum Dry Extract
Given in Combination with Salidroside on BE in Female Rats.
Additional eighty female rats received the same procedures of
the NR + NS and R + S rats in the Experiments 1 and 2. On
the test day (day 25), NR + NS and R + S rats were treated by
gavage as follows (10 rats per group): (a) vehicle + vehicle,
(b) vehicle + Salidroside 312 µg/kg, and (c) Hypericum per-
foratum extract 125mg/kg + vehicle, Hypericum perforatum
extract 125mg/kg + Salidroside 312 µg/kg. Food intake was
expressed as mean kcal/kg ingested ± S.E.M. HPF intake was
measured at 15, 30, 60, and 120min after access to it. Food
pellet intake was measured only at 2 h.
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Experiment 4. Effect of Hypericum perforatum Extract and
Salidroside on Serum Corticosterone Levels Following Cycles of
Food Restriction and Exposure to Acute Stress
Experiment 4a. To assess if the doses of Hypericum perfora-
tum extract (250 and 500mg/kg) that reduced BE have an
effect on the increased corticosterone levels in the R + S
group, additional fifty-four Sprague-Dawley rats were used.
They were divided in two groups (NR + NS and R + S) of
27 animals, were subjected to three cycles of 8 days with
the same procedure described under Experiment 1. At the
end of the third cycle (on day 25) in each group, 9 animals
received vehicle, 9 animals received Hypericum perforatum
dry extract, 250mg/kg, and other 9 rats received Hypericum
perforatum dry extract, 500mg/kg. The R + S group received
drug administration 45min before exposure to the stressful
procedure and was sacrificed at the end of the 15min period
of stress. The NR + NS group was administered vehicle or
Hypericum perforatum dry extract, 250 or 500mg/kg and
then sacrificed 60min later.
Experiment 4b. Additionally forty-five Sprague-Dawley rats,
divided in two groups: NR + NS (n = 9) and R +
S (n = 36), were subjected to three cycles of 8 days
with the same procedure described under Experiment 1.
At the end of the third cycle (on day 25), 9 NR + NS
rats received vehicle + vehicle, R + S rats were divided in
four groups of 9 animals that received: vehicle + vehicle,
vehicle + Salidroside 312 µg/kg, Hypericum perforatum dry
extract (125mg/kg) + vehicle, and Hypericum perforatum dry
extract (125mg/kg) and salidroside 312 µg/kg. The R + S
group received drug administration 45min before exposure
to the stressful procedure and was sacrificed at the end
of the 15min period of stress. The NR + NS group was
administered vehicle and then sacrificed 60min later.
Blood samples were collected from the rat trunk after
decapitation. To improve serum separation from whole
blood, samples were allowed to clot at room temperature
before centrifugation (1000×g for 10min). Serumwas trans-
ferred into clean tubes and stored at −20◦C until the assay.
Taking into account the circadian rhythm of corticosterone,
all sacrifices were carried out between 12.00 and 2.00 p.m.,
that is, during the diurnal period when its concentrations
are relatively constant [77, 78]. Assessment of serum corti-
costerone level was done by means of enzyme immunoassay
(EIA) using a commercially available kit (Arbor Assays, Ann
Arbor, MI, USA), which utilizes microplate reader set at
450 nm. Serum samples were diluted 1 : 100 in appropriate
assay buffers in order to be within the calibration curve range
and assayed in duplicate. The detection limit of the assay was
16.9 pg/mL; intra- and interassay coefficients of variations
were, respectively, 5.1 and 7.9%.
2.6. Statistical Analysis. Results are expressed as means ±
S.E.M. Data were analyzed by two-ways analysis of variance
(ANOVA) with between-subject comparisons for experi-
mental groups or drug treatments and within-subject com-
parison for time of observation when appropriate (Systat
13.0). Post hoc comparison was carried out by the Bonferroni
test. Statistical significance was set at P < 0.05.
3. Results
Experiment 1. Effect of Repeated Food Restrictions and Acute
Stress of HPF Intake in Female Rats. Thirty female rats (of the
40 used in the experiment) proved not to be in the estrous
phase at the moment in which the experiment was carried
out. Only data from these animals (6–8 per group) were
subjected to statistical analysis.
As shown in Figure 1, body weight of rats was reduced
during the 4 days of food restriction, but immediately
afterwards the animals increased their food intake and
rapidly recovered their body weight to control levels by the
end of each cycle. On the test day, body weight of the 4 groups
of animals, as well as their food intake in the previous 24 h,
was not significantly different.
The ANOVA revealed a highly significant difference in
2 h HPF intake in the 4 groups of rats (F(3, 26) = 19.32;
P < 0.001). As shown in Figure 2 and in Table 1, HPF
intake in the R + S group was markedly higher than that
of the control (NR + NS) group. HPF intake of R + S
rats was very pronounced in the first 15min of access to it;
these animals never engaged in competing behaviours, but
continuously remained over the cup containing HPF and
focused their attention on the intake. Cumulative HPF intake
in the R + S group was significantly higher than in controls
up to 120min after access to it. HPF intake of the NR + S
group was not significantly different from that of controls
(NR + NS), indicating that stress was not enough to induce
BE. Moreover, also HPF intake of the R + NS group was
not significantly different from that of controls (NR + NS),
indicating that cycles of food restriction are not enough to
induce BE.
The intake of standard food pellet was very small (about
3–5% of the overall calories intake in the 2 h test), and it was
affected neither by food restriction, nor by stress, and nor by
the combination of both. In the 2 h test, rats of the R + S
group ate 176.2 kcal/kg of HPF and only 6.5 kcal/rat of food
pellets.
Experiment 2. Effect of Hypericum perforatum Extract on
BE Evoked by Cycles of Food Restriction and Exposure to
Acute Stress. Fifty-seven female rats (of the 80 used in the
experiment) proved not to be in the estrous phase at the
moment in which the experiment was carried out. Only
data from these animals (6–8 per group) were subjected to
statistical analysis. As shown in Figure 3, following vehicle
administration, HPF intake in the R + S group was markedly
higher than that of the NR +NS group. The ANOVA revealed
a highly significant difference in 2 h HPF intake in the 2
groups of rats following vehicle administration (F(1, 12) =
16.88; P < 0.01).
As shown in Figure 3, in the NR +NS group, the ANOVA
revealed a nonsignificant treatment effect (F(3, 25) =
2.82; P = 0.059). Following the highest dose of 500mg/kg
of Hypericum perforatum extract, a marked trend to the
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Figure 1: Body weight of female rats during the three 8-day cycles
of food restriction/refeeding. Values are means ± S.E.M.
15 30 60 120
0
20
40
60
80
100
120
140
160
180
H
P
F 
in
ta
ke
 (
kc
al
/k
g)
Time (min)
NR + NS
NR + S
R + NS
R + S
∗∗
∗∗
∗∗ ∗∗
Figure 2: HPF intake (kcal/kg) on the test day in female rats
exposed to either cycles of food restriction or stress or the
combination of both. Data are means ± S.E.M. Statistical difference
from controls (NR + NS): ∗∗P < 0.01.
Table 1: HPF intake in grams on the test day in female rats exposed
to either cycles of food restriction or stress or the combination of
both. Data are means ± S.E.M. Statistical difference from controls
(NR + NS): ∗∗P < 0.01.
Group 15min 30min 60min 120min
NR + NS 6.6 ± 0.2 7.6 ± 0.3 9.0 ± 0.3 9.8 ± 0.3
NR + S 6.2 ± 0.1 7.7 ± 0.6 8.6 ± 0.6 9.8 ± 0.4
R + NS 7.6 ± 0.6 8.1 ± 0.6 9.4 ± 0.8 10.6 + 1.2
R + S 10.5 ± 0.4∗∗ 11.9 ± 0.4∗∗ 12.9 ± 0.4∗∗ 13.3 + 0.5∗∗
reduction of HPF intake was observed, but the difference was
not statistically significant.
The Hypericum perforatum extract significantly reduced
HPF intake in the R + S group (F(3, 24) = 7.41; P < 0.001).
The effect was statistically significant only at 15min follow-
ing administration of 250mg/kg and up to 60min following
administration of 500mg/kg; the dose of 125mg/kg did not
significantly reduce BE.
Experiment 3. Effect of Hypericum perforatum Dry Extract
Given in Combination with Salidroside on BE in Female
Rats. Sixty female rats (of the 80 used in the experiment)
were not in the estrous phase (6–9 per group). Following
vehicle administration, a highly significant difference in
2 h HPF intake in the 2 groups of rats following vehicle
administration was observed (data of NR + NS group were
not shown).
The ANOVA revealed a highly significant treatment effect
only in R + S group (F(3, 28) = 5,98; P < 0.01).
As shown in Figure 4, Hypericum perforatum extract
(125mg/kg) did not significantly modify HPF intake.
Salidroside (312 µg/kg) reduced HPF intake; the combi-
nation of Hypericum perforatum extract (125mg/kg) and
Salidroside (312 µg/kg) increased the reduction of HPF
in comparison to that observed after Salidroside alone.
Following Salidroside (312 µg/kg) treatment, the difference
from vehicle-treated rats was statistically significant only
at 15min (P < 0.05); with Hypericum perforatum extract
(125mg/kg) and Salidroside (312 µg/kg), the effect was
statistically significant up to 60min (P < 0.05).
Thus, when the dose of 125mg/kg of Hypericum perfora-
tum extract (i.e., per se inactive) was administered together
with Salidroside 312 µg/kg, the antibinge effect proved to be
more intense, longer lasting, and reached the level of P < 0.01
as statistical significance in comparison to the effect observed
following Salidroside 312 µg/kg alone (P < 0.05).
Experiment 4. Effect of Hypericum perforatum Extract and
Salidroside on Serum Corticosterone Levels Following Cycles of
Food Restriction and Exposure to Acute Stress
Experiment 4a. Forty-two female rats (of the 54 used in the
experiment) were not in the estrous phase at the moment in
which the experiment was carried out (6–8 per group).
Two-way ANOVA showed significant group effect (F(1,
36) = 20.7, P < 0.01). As reported in Figure 5, exposure
to HPF without access to it significantly increased corticos-
terone levels in the serum samples obtained from R + S rats,
in comparison to those from NR + NS rats (Bonferroni post
hoc test, P < 0.05).
On the other hand, the ANOVA revealed neither a
drug treatment effect (F(2, 36) = 3.3, P > 0.05), nor a
group-drug treatment interaction (F(2, 36) = 0.1, P > 0.05)
on serum corticosterone levels. The administration by
gavage of Hypericum perforatum extract at either dose used
(250 or 500mg/kg) failed to reduce the increase in serum
corticosterone levels in the R + S group. Post hoc tests showed
that serum corticosterone levels in R + S rats, treated with the
2 doses of Hypericum perforatum extracts, were comparable
to those of R + S rats treated with vehicle (P > 0.05), but
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Figure 3: Effect of intragastric administration of different doses of Hypericum perforatum extract or vehicle on HPF intake on the test day
in R + S and NR + NS rats. Data are means ± S.E.M. Statistical difference from vehicle-treated rats: ∗P < 0.05; ∗∗P < 0.01.
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Figure 4: Effect of the combined administration of Hypericum
perforatum extract, 125mg/kg, and Salidroside 312 µg/kg on HPF
intake on the test day in R + S rats. Data are means ± S.E.M.
Statistical difference from vehicle + vehicle-treated rats: ∗P < 0.05,
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were statistically different from those of NR + NS rats, either
treated or not treated with Hypericum perforatum.
Experiment 4b. Thirty-six female rats (of the 45 used in the
experiment) were not in the estrous phase at the moment in
which the experiment was carried out (6–9 per group).
Two-way ANOVA showed significant group effect (F(1,
34) = 93.4, P < 0.01). As reported in Figure 6, exposure
to HPF without access to it significantly increased corticos-
terone levels in the serum samples obtained from R + S rats,
in comparison to those from NR + NS rats (Bonferroni post
hoc test, P < 0.01).
On the other hand, the ANOVA revealed no drug
treatment effect in R + S group (F(3, 23) = 1.64, P > 0.05) on
serum corticosterone levels.
4. Discussion
The present study confirms that stress or repeated food
restrictions, given separately, are not enough to induce
BE, but the combination of both determinants is required.
Previous work by Cifani et al. [40] has shown that the
experimental model of BE adopted in the present study
possesses, in addition to face and construct validity, also
predictive validity, since both topiramate and sibutramine
abolish BE.
The administration by gavage of a dry extract of
Hypericum perforatum, 250mg/kg, significantly reduced the
increase in HPF intake in the R + S group (subjected to
both stress and repeated food restrictions), and the dose
of 500mg/kg completely reduced it. On the other hand,
125mg/kg did not significantly influence HPF intake in the
R + S group. While suppressing the increase in HPF intake
in the R + S group, the three doses tested of Hypericum
perforatum extract did not significantly reduce HPF in the
control group (NR + NS) even if a clear trend of reduction
was shown by the highest tested dose (500mg/kg).
The mechanisms accounting for this selective effect on
BE remain to be elucidated. As mentioned in the Introduc-
tion, Hypericum perforatum extracts have been reported to
influence stress mechanisms. Several papers have shown that
some of its active principles bind to CRF-1 receptors and
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500mg/kg) or its vehicle on serum corticosterone levels in R + S
rats and in NR + NS rats. Data are means± S.E.M (n = 6–8 rats per
group). Statistical difference vehicle R + S rats versus vehicle NR +
NS: #P < 0.05; statistical difference from vehicle-treated rats in each
group was never statistically significant.
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Figure 6: Effect of the combined administration of Hypericum
perforatum extract, 125mg/kg, and Salidroside 312 µg/kg on serum
corticosterone levels in R + S rats. Data are means± S.E.M (n = 6–8
rats per group). Statistical difference vehicle R + S rats versus vehicle
NR + NS: ##P < 0.01; statistical difference from vehicle-treated rats
in R + S group was never statistically significant.
exhibit antagonist activity at these receptors [64–67]. More-
over, Hypericum perforatum extracts have been reported
to reduce HPA axis activation following chronic treatment
[68] and to reduce restraint stress-induced increases in
plasma ACTH and corticosterone levels following acute
administration [69]. Corticosterone has been proposed to
have motivational properties and to influence drug-seeking
behaviour in rats [79–82], suggesting that it may have a role
in the control of compulsive behaviour, like that exhibited
in episodes of BE. However, a recent study of our group has
shown that peripheral administration of corticosterone is not
able to induce BE in rats exposed to repeated cycles of food
restrictions; moreover, metyrapone, a glucocorticoid synthe-
sis inhibitor, does not affect BE [83]. On the other hand,
the same study has shown that a CRF-1 receptor antagonist
completely blocks BE in the experimental model adopted
[83]. Taken together, these findings suggest that CRF controls
BE through CRF-1 receptors mainly in extrahypothalamic
brain areas, rather than in the hypothalamic structures
controlling the HPA axis. The results of Experiment 3
indicate that in our experimental conditions Hypericum
perforatum does not influence HPA axis activation; however,
it cannot be excluded that it abolishes BE by blocking central
CRF-1 receptors in extrahypothalamic brain area.
On the other hand, the inhibition of the BE may be
achieved also by suppressing addictive-like behaviours, in
particular those related to the binge/intoxication stages of
addiction [84]. In this regard, it is interesting to note
that Hypericum perforatum has been reported to suppress
voluntary alcohol intake, ethanol self-administration and
the alcohol-deprivation effect in genetically selected alcohol-
preferring rats [44–50, 75], including the Marchigian Sar-
dinian alcohol-preferring rats that represent an interesting
experimental model of alcohol abuse [85]. Therefore, Hyper-
icum perforatum may influence motivation and compulsive
behaviours towards HPF in BE episodes, as it does towards
alcohol.
Among the active principles identified in Hypericum
perforatum extracts, apparently pseudohypericin is the most
potent CRF-1 receptor antagonist [68], but also hypericin
exhibited high binding affinity for human CRF-1 receptors
[65]. Other Hypericum perforatum constituents with high
affinity for the CRF-1 receptor are also bisanthraquinone gly-
cosides [64] and flavonoids [68]. Hyperforin and hyperforin
derivatives do not bind with high affinity at CRF1 receptors
and are not involved in the control of HPA axis function [86].
On the other hand, hyperforin has been proposed to be the
main active principle responsible for the effect of Hypericum
perforatum in the control of alcohol abuse [75]. The extract
used in the present study had a very low hypericin content
(0.1%) and a rather high hyperforin content (3.8%). These
data favour the hypothesis that hyperforin may have a major
role in the suppressive effect of Hypericum perforatum on BE;
accordingly, the mechanism of action may be more likely
related to suppression of addictive-like behaviours than to
interference with stress mechanisms.
It is interesting to note that Hypericum perforatum was
able to increase the effect of Salidroside, that in our previous
study, showed to be the active principle of Rhodiola rosea
extracts responsible for the selective effect in reducing BE
[73].
Recently, the effect of Salidroside on expression and
secretion of neuropeptide Y (NPY) in neuroglia cells has
been demonstrated [87]. Since it is well documented that
NPY reduces consummatory ingestive behaviour by about
8 Journal of Obesity
40% [88, 89], it has been suggested [87] that the effect of
Salidroside on BE is mediated by NPY.
In conclusion, the present findings suggest that Hyper-
icum perforatum extracts and Salidroside may be useful for
treatment of bingeing-related eating disorders.
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